University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 6 of 35
Near Infrared Spectroscopy (NIRS) for Assessment of Depression
NCT04061148
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
NCT03729752
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
NCT03933670
Autologous Gene Therapy for Artemis-Deficient SCID
NCT03538899
Pharmacokinetics Distribution of Raltegravir by PET/MR
NCT03174977
Biomarkers for Risk Stratification in Lung Cancer
NCT03774758
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
NCT06940323
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
NCT02521311
International Registry of Patients With Alpha Thalassemia
NCT04872179
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
NCT02620852
Packing Versus no Packing for Cutaneous Abscess
NCT02822768
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT03011684
Clinical and Biological Characteristics of Hidradenitis Suppurativa
NCT03967600
Inflammation, Diabetes, Ethnicity and Obesity Cohort
NCT03022682
Stroke Recovery Initiative - Registry for Stroke Research Studies
NCT03318432
Functional Assessment in Liver Transplantation
NCT03228290
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
NCT01202305
The Use of Leukapheresis to Support HIV Pathogenesis Studies
NCT01161199
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease
NCT00904878
Retinal Imaging in Patients With Inherited Retinal Degenerations
NCT00254605
SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era
NCT00187512
Collection of Blood for Multiple Collaborative Studies
NCT01336855
Health Advocate for Children After Liver Transplant
NCT07279350
The Effect of Grocery Support Dose on Food Insecurity and Disease Control Among Covered California Members With Diabetes or Hypertension
NCT07469995
Blood Flow Restriction and Exercise in Parkinson's Disease
NCT07221994
Medical Improvisation Study
NCT07355998
Empowering Newcomer Voices: A Trauma-Informed, Gender-Responsive Group Intervention in Schools (VOCES-NUEVAS)
NCT07041931
Optimizing an Integrated Mind and Body Treatment for Insomnia: The SLEEPS Study
NCT06626048
Evaluating Covered California's Grocery Support Program
NCT07215897
Music, Social Attention, and Dementia
NCT06768996
TMS-EEG Biomarkers for Chronic Pain
NCT07116278
Post-Radiation Oral Health in Underserved Head and Neck Cancer Patients
NCT07556367
Accelerating Cognitive Gains From Digital Inverventions With Noninvasive Brain Stimulation
NCT06633952
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
NCT05924672
Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases
NCT06585670
Mindful Motivation for Reducing Binge Eating
NCT06528067
Cataract Monitored Anesthesia Care (MAC) Feasibility Pilot Study
NCT06506669
Music Improvisation Training on Cognitive Function in Older Adults
NCT06721390
FostrSpace-CASA R61/R33
NCT06875323
The MARY-JANE Cannabis and Heart Rhythm Trial
NCT06021613
Continuous Glucose Monitoring System Feasibility in Youth With T2D
NCT06089070
Intervention for Virologic Suppression in Youth
NCT05877729
Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome
NCT06050265
Addressing Unmet Social Needs Among Hospitalized Children
NCT05968716
Heart Health After Cancer Treatment (HEART-ACT)
NCT06055803
Identifying Networks Underlying Compulsivity in Anorexia Nervosa for Targeting With Neuromodulation
NCT06138782
Dynamic Neural Systems Underlying Social-emotional Functions in Older Adults
NCT05645835
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI
NCT05845749
A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis
NCT05865405
Ocular Rosacea Biome Study
NCT05296837
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets.Report a data error.